Celularity Inc.
NASDAQ:CELU
Overview | Financials
Company Name | Celularity Inc. |
Symbol | CELU |
Currency | USD |
Price | 2.24 |
Market Cap | 50,364,608 |
Dividend Yield | 0% |
52-week-range | 1.3 - 7.97 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Robert Joseph Hariri M.D., Ph.D. |
Website | https://www.celularity.com |
An error occurred while fetching data.
About Celularity Inc.
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD